3Z Pharmaceuticals Publishes Breakthrough Study on Shared Metabolic Pathways in ADHD Therapeutics

REYKJAVIK, Iceland, Feb. 24, 2025 /PRNewswire/ -- 3Z Pharmaceuticals, a CNS-focused therapeutic development specialist, today announced the publication of a groundbreaking study in The Journal of Pharmacology and Experimental Therapeutics, unveiling...